Matches in SemOpenAlex for { <https://semopenalex.org/work/W2222727161> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2222727161 abstract "e19016 Background: Approximately 40% of NSCLC pts present with metastatic disease where treatment is considered palliative. Here we examine whether prolonged survival is possible in a sizeable proportion of NSCLC pts with good PS and stage IV disease particularly given the availability of personalized chemotherapy approaches. Methods: NSCLC pts with stage IV disease and an ECOG PS of 0/1 were prospectively accrued to four phase II clinical trials, at the H. Lee Moffitt Cancer Center and treated with the following regimens; Trial A) carboplatin/gemcitabine first-line followed by docetaxel second-line, Trial B) docetaxel and gefitinib combination therapy in patients aged 70 years or older, Trial C) combination therapy with carboplatin/paclitaxel/atrasentan, Trial D) personalized therapy (PT) based on ERCC1 and RRM1. Pts with low RRM1/low ERCC1 received gemcitabine/carboplatin; low RRM1/high ERCC1, gemcitabine/docetaxel; high RRM1/low ERCC, docetaxel/carboplatin; high RRM1/high ERCC1, vinorelbine/docetaxel. Data were updated as of 10/23 / 08. Overall survival was estimated using the piecewise exponential survival function which showed a dramatic shift at 29 months. Results: A total number of 181 pts were accrued. The median survival for the entire cohort was 10.5 months improving dramatically to 85.3 months, if alive at 29 months (adjusted P = 0.005). In the entire cohort, 16.7% of pts survived to 29 months compared to 25% of pts in the PT group. For pts who were alive at 29 months, the probabilities of surviving to 48, 60, 72 and 84 months were 79%, 68%, 59% and 51%, respectively. Conclusions: Long term survival is possible in a sizeable proportion of stage IV NSCLC with good PS. Our treatment paradigm should shift from palliation to achieving long term survival. Molecularly-based PT may be one way of achieving this goal. No significant financial relationships to disclose." @default.
- W2222727161 created "2016-06-24" @default.
- W2222727161 creator A5034393552 @default.
- W2222727161 creator A5041062966 @default.
- W2222727161 creator A5054228590 @default.
- W2222727161 creator A5055925608 @default.
- W2222727161 creator A5057369839 @default.
- W2222727161 creator A5064494204 @default.
- W2222727161 creator A5080538468 @default.
- W2222727161 date "2009-05-20" @default.
- W2222727161 modified "2023-09-23" @default.
- W2222727161 title "Evidence for long-term survival in a sizeable proportion of good performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC)" @default.
- W2222727161 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e19016" @default.
- W2222727161 hasPublicationYear "2009" @default.
- W2222727161 type Work @default.
- W2222727161 sameAs 2222727161 @default.
- W2222727161 citedByCount "0" @default.
- W2222727161 crossrefType "journal-article" @default.
- W2222727161 hasAuthorship W2222727161A5034393552 @default.
- W2222727161 hasAuthorship W2222727161A5041062966 @default.
- W2222727161 hasAuthorship W2222727161A5054228590 @default.
- W2222727161 hasAuthorship W2222727161A5055925608 @default.
- W2222727161 hasAuthorship W2222727161A5057369839 @default.
- W2222727161 hasAuthorship W2222727161A5064494204 @default.
- W2222727161 hasAuthorship W2222727161A5080538468 @default.
- W2222727161 hasConcept C126322002 @default.
- W2222727161 hasConcept C141071460 @default.
- W2222727161 hasConcept C143998085 @default.
- W2222727161 hasConcept C207103383 @default.
- W2222727161 hasConcept C2776256026 @default.
- W2222727161 hasConcept C2776694085 @default.
- W2222727161 hasConcept C2776907518 @default.
- W2222727161 hasConcept C2778239845 @default.
- W2222727161 hasConcept C2780258809 @default.
- W2222727161 hasConcept C2780350996 @default.
- W2222727161 hasConcept C2781190966 @default.
- W2222727161 hasConcept C2781451048 @default.
- W2222727161 hasConcept C44249647 @default.
- W2222727161 hasConcept C71924100 @default.
- W2222727161 hasConceptScore W2222727161C126322002 @default.
- W2222727161 hasConceptScore W2222727161C141071460 @default.
- W2222727161 hasConceptScore W2222727161C143998085 @default.
- W2222727161 hasConceptScore W2222727161C207103383 @default.
- W2222727161 hasConceptScore W2222727161C2776256026 @default.
- W2222727161 hasConceptScore W2222727161C2776694085 @default.
- W2222727161 hasConceptScore W2222727161C2776907518 @default.
- W2222727161 hasConceptScore W2222727161C2778239845 @default.
- W2222727161 hasConceptScore W2222727161C2780258809 @default.
- W2222727161 hasConceptScore W2222727161C2780350996 @default.
- W2222727161 hasConceptScore W2222727161C2781190966 @default.
- W2222727161 hasConceptScore W2222727161C2781451048 @default.
- W2222727161 hasConceptScore W2222727161C44249647 @default.
- W2222727161 hasConceptScore W2222727161C71924100 @default.
- W2222727161 hasLocation W22227271611 @default.
- W2222727161 hasOpenAccess W2222727161 @default.
- W2222727161 hasPrimaryLocation W22227271611 @default.
- W2222727161 hasRelatedWork W1873996393 @default.
- W2222727161 hasRelatedWork W1985684555 @default.
- W2222727161 hasRelatedWork W2115178301 @default.
- W2222727161 hasRelatedWork W2151338657 @default.
- W2222727161 hasRelatedWork W2165963900 @default.
- W2222727161 hasRelatedWork W2222727161 @default.
- W2222727161 hasRelatedWork W2242763718 @default.
- W2222727161 hasRelatedWork W2351358978 @default.
- W2222727161 hasRelatedWork W2439707001 @default.
- W2222727161 hasRelatedWork W2993175924 @default.
- W2222727161 isParatext "false" @default.
- W2222727161 isRetracted "false" @default.
- W2222727161 magId "2222727161" @default.
- W2222727161 workType "article" @default.